Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.280
+0.160 (7.55%)
At close: Jun 27, 2025, 4:00 PM
2.210
-0.070 (-3.07%)
After-hours: Jun 27, 2025, 7:54 PM EDT
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$145,679
Profits / Employee
-$1,021,264
Market Cap
190.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
EDIT News
- 16 days ago - Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 5 weeks ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 6 weeks ago - Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 6 weeks ago - Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 6 weeks ago - Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 6 weeks ago - Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 6 weeks ago - Editas Medicine Announces First Quarter 2025 Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board - GlobeNewsWire